30 Apr , 2025 By : Debdeep Gupta
Alembic Pharma share price extended the gains on second day, rising 1 percent in the early trade on April 30 following Establishment Inspection Report (EIR) for its Panelav-based oncology formulation facility.
At 09:20am, Alembic Pharmaceuticals was quoting at Rs 888.45, up Rs 9.20, or 1.05 percent, on the BSE.
US Food and Drug Administration (USFDA) has carried out inspection at the said between from October 7-8 October, 2024.
".... has received an Establishment Inspection Report (EIR) from the US Food and Drug Administration (USFDA) for the inspection carried out by them at our oncology formulation facility injectable and oral solid) (F-2) at Panelav from 7th October, 2024 to 8th October, 2024," company said in its press release.
On April 26, the company has commissioned a new manufacturing facility located at Pithampur, Dist: Dhar, Madhya Pradesh, for manufacturing of formulations.
A meeting of board of directors of the company will be held on May 6, 2025, to consider audited financialrResults of the company for the quarter and financial year ended 31st March, 2025 and recommend dividend on equity shares, if any, for the financial year ended 31st March, 2025.
The share price declined 28 percent in the last nine months.
The share touched a 52-week high of Rs 1,296.15 and a 52-week low of Rs 725.60 on 09 October, 2024 and 03 March, 2025, respectively.
Currently, the stock is trading 31.45 percent below its 52-week high and 22.44 percent above its 52-week low.
The market capitalisation stands at Rs 17,463.65 crore.
In the month of March, USFDA has completed the inspection of the company's API-III facility at Karakhadi, with no Form 483 observations.
0 Comment